PET/CT引导组织取样在CT引导操作失败或结果不确定患者中的应用:结局与影响因素
前瞻性纳入111例至少一次CT引导操作失败或结果不确定的患者,106例在诊断性F-FDG PET/CT可行性分析后行PET/CT引导取样(活检80例、细针穿刺细胞学26例),使用机械臂和74至111 MBq(2-3 mCi)F-FDG低剂量静脉注射。F-FDG高摄取病灶总体精准靶向率为77.36%(活检86.25%+细针穿刺细胞学50%),影响靶向的显著因素为操作类型、患者移动和操作时长。总体并发症率21.70%,主要并发症4.71%,并发症与靶灶深度相关。
要点
- CT引导失败或不确定时,PET/CT引导取样F-FDG高摄取病灶精准靶向率为77.36%。
- 活检精准靶向率86.25%,细针穿刺细胞学为50%。
- 操作类型(活检vs细针穿刺细胞学;OR 5.916;P=0.002)、患者移动(OR 0.275;P=0.023)、操作时长(OR 1.195;P=0.011)为显著参数。
核心结论
- 作者认为,在CT引导活检失败或结果不确定时,应考虑PET/CT引导取样。
- 结局受穿刺针规格和患者移动影响,并发症率取决于靶灶深度。
研究设计与样本
- 前瞻性纳入111例至少1次CT引导操作失败或结果不确定的患者,106例在诊断性F-FDG PET/CT可行性分析后行PET/CT引导取样(女45例、男61例;平均年龄48.09±15.42岁;活检80例、细针穿刺细胞学26例),使用机械臂和74至111 MBq(2-3 mCi)F-FDG低剂量静脉注射。
主要发现
- 81例实现精准病灶靶向(63例阳性病灶、12例混杂病灶、7例样本不足),5例未命中病灶,19例取到血液/坏死组织。
- F-FDG高摄取病灶总体精准靶向率为77.36%(活检86.25%+细针穿刺细胞学50%)。
- 影响靶向的显著变量为穿刺针规格、偏离预定进针点、操作时长、操作类型和患者移动;二项回归中显著参数为操作类型(活检vs细针穿刺细胞学;OR 5.916;P=0.002)、患者移动(OR 0.275;P=0.023)、操作时长(OR 1.195;P=0.011)。
- 总体并发症率21.70%,主要并发症4.71%;并发症组靶灶平均深度69.74±20.29 mm vs 无并发症组47.18±22.60 mm(P<0.001)。
- 靶灶深度与穿刺针偏离预定靶点距离呈正相关(Spearman ρ=0.307;P=0.001);28例操作中要求医师佩戴口袋剂量计,平均受照剂量2.52(SD 3.10)μSv。
关键数值与推荐
- F-FDG高摄取病灶总体精准靶向率为77.36%(活检86.25%+细针穿刺细胞学50%)。
- 操作类型(活检vs细针穿刺细胞学;OR 5.916;P=0.002)、患者移动(OR 0.275;P=0.023)、操作时长(OR 1.195;P=0.011)为显著参数。
- 总体并发症率21.70%,主要并发症4.71%;并发症组靶灶平均深度69.74±20.29 mm vs 无并发症组47.18±22.60 mm(P<0.001)。
- 靶灶深度与穿刺针偏离预定靶点距离正相关(Spearman ρ=0.307;P=0.001)。
- 28例操作中醫師佩戴口袋剂量计,平均受照剂量2.52(SD 3.10)μSv。
临床怎么用
- 作者认为,在CT引导活检失败或结果不确定时,应考虑PET/CT引导取样。
- 作者指出结局受穿刺针规格和患者移动影响,并发症率取决于靶灶深度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CT-guided tissue sampling is a very effective tool. However, false-negative results are obtained when regions such as necrotic core or surrounding reactive fibrosis and inflammation are sampled. PET/CT-guided sampling can circumvent these limitations. PURPOSE: The aim of this study was to analyze the effectiveness of PET/CT-guided sampling in patients with at least 1 instance of failed or inconclusive CT-guided procedure and factors determining the accurate sampling and complications. METHODS: One hundred eleven patients were prospectively included. After feasibility analysis in a diagnostic F-FDG PET/CT, sampling was performed in 106 patients (45 women, 61 men; mean age, 48.09 ± 15.42 years; biopsy in 80 and fine-needle aspiration cytology [FNAC] in 26 patients), using robotic arm and a lower IV injection dose of 74 to 111 MBq (2-3 mCi) F-FDG. In all patients, final check scans revealed needle at the target site. Using planned needle path as reference, deviations in first check scan were measured. Patient (n = 30) and respiratory motion (n = 57) were also recorded. RESULTS: Accurate lesion targeting was achieved in 81 cases (63 positive lesions, 12 confounding lesions, and 7 inadequate samples). Lesion was missed in 5 instances, and blood/necrotic tissue sampled in 19. Overall F-FDG-avid lesions were accurately targeted in 77.36% of patients (86.25% [biopsy] + 50% [FNAC]). Significant variables affecting targeting were needle gauge, deviation from intended entry point, procedure duration, procedure type, and patient movement. Using binomial regression, the significant parameters were procedure type (biopsy vs FNAC; odds ratio [OR], 5.916; P = 0.002), patient movement (OR, 0.275; P = 0.023), and procedure duration (OR, 1.195; P = 0.011). Overall complication rate was 21.70%, with 4.71% major complications. It was dependent on target depth (mean depth, 69.74 ± 20.29 mm [complications] vs 47.18 ± 22.60 mm; P < 0.001). Positive correlation was seen between the target depth and distance of needle from the intended target (Spearman ρ = 0.307; P = 0.001). In 28 procedures, the physician was asked to wear a pocket dosimeter, who received a mean dose of 2.52 (SD, 3.10) μSv. CONCLUSIONS: PET/CT-guided sampling should be considered where CT-guided biopsy has failed or is inconclusive. The outcome is impacted by needle gauge and patient movement, and complication rate is dependent on target depth.
引用
- Kumar R, Sharma A, Thulkar S, et al. PET/CT-Guided Tissue Sampling in Patients With a Failed or Inconclusive CT-Guided Procedure: Outcomes and Contributing Factors. Clin Nucl Med. 2020. PMID: 32558712. doi:10.1097/RLU.0000000000003128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。